Streetbeat News

Products Services

ETHUSD

Bored Ape #2333, a non-fungible token (NFT) from the Bored Ape Yacht Club (BAYC) collection, has been sold for 74 ETH ($134,523 USD). BAYC is an exclusive community for holders of ape and mutant-themed NFTs on Ethereum's blockchain, with only 10,000 generative art pieces ever to be created.

Portfolio Pulse from Benzinga Insights

May 19, 2023 | 7:00 pm

TSLA

Tesla is offering discounts of over $1,300 on some Model 3 cars in its U.S. inventory, potentially indicating an attempt to boost sales.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 6:51 pm

META

Rap artist Busta Rhymes praised entrepreneur Gary Vaynerchuk during his performance at VeeCon 2023, a business, tech, and pop culture conference. Busta Rhymes highlighted Vaynerchuk's relatable communication style and captivating energy. The rapper also mentioned using Meta Platforms Inc's (NASDAQ:META) Instagram app to watch Gary Vee's videos.

Portfolio Pulse from Adam Eckert

May 19, 2023 | 6:27 pm

META

Meta Platforms is reportedly planning to launch a Twitter-like text app on Instagram by late June. The app will feature a single sign-in with Instagram details, text posts of up to 500 characters, and the ability to attach links, photos, and videos. This comes amid Elon Musk's plans to expand features on Twitter.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 6:25 pm

KRYS

Krystal Biotech has received FDA approval for its first-ever redosable gene therapy, VYJUVEK, for the treatment of Dystrophic Epidermolysis Bullosa (DEB). The topical gel addresses the genetic cause of DEB by restoring functional copies of the COL7A1 gene. The Phase 3 trial met its primary and secondary endpoints, and the company will host an investor conference call on May 19, 2023.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 6:04 pm

AMAM

Cantor Fitzgerald initiated coverage on Ambrx Biopharma Inc (NASDAQ: AMAM) with an Overweight rating and a price target of $25. The analyst believes the peak sales potential of Ambrx's pipeline of antibody-drug conjugates (ADCs) is underappreciated and that the company has sufficient capital to execute its development plans into 2025.

Portfolio Pulse from Vandana Singh

May 19, 2023 | 6:04 pm

ABBV

GMAB

The FDA has approved Epkinly, a T-cell engaging bispecific antibody for adult patients with relapsed or refractory diffuse large B-cell lymphoma, co-developed and co-commercialized by Genmab A/S (GMAB) and AbbVie Inc (ABBV). The drug demonstrated a 61% overall response rate and 38% complete remission in a Phase 2 study.

Portfolio Pulse from Vandana Singh

May 19, 2023 | 5:59 pm

ABT

STXS

Stereotaxis Inc (STXS) and Abbott Laboratories (ABT) have announced a global collaboration to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems. The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months. The FDA also approved Abbott's TactiFlex Ablation Catheter, Sensor Enabled.

Portfolio Pulse from Vandana Singh

May 19, 2023 | 5:23 pm

ABBV

The U.S. FDA has approved AbbVie's EPKINLY (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). EPKINLY is being co-developed by AbbVie and Genmab as part of their oncology collaboration.

Portfolio Pulse from Benzinga Newsdesk

May 19, 2023 | 4:37 pm

BABA

MSFT

Alibaba (NYSE:BABA) reported Q4 revenue of $29.6 billion, up 2% YoY but missing estimates, and adjusted net profit of $4.0 billion, up 38% YoY. The company plans to spin off its cloud unit to compete with Amazon and Microsoft (NASDAQ:MSFT). Alibaba's AI technology is expected to drive growth in its cloud computing service.

Portfolio Pulse from Upwallstreet

May 19, 2023 | 4:34 pm